QRxPharma Limited (QRXPY: OTCQX International) | QRxPharma

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
QRxPharma Limited (QRXPY: OTCQX International) | QRxPharma Announces Board Resignations QRxPharma Announces Board Resignations

QRxPharma Announces Board Resignations

PR Newswire

SYDNEY and BEDMINSTER, N.J., July 9, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting. 

The Company also announces that directors Peter Campbell and Michael Quinn have tendered their resignations from the QRxPharma board. In order to facilitate an orderly transition, their resignations will take effect at 5:00pm (AEST) 11 July 2014 or at such earlier time the newly elected directors can appoint one or more replacements.

"It has been an honour serving as QRxPharma chairman and I certainly share the frustration of shareholders with respect to the development of Moxduo and interactions with the FDA," said Dr. Farrell.  "Speaking for the entire outgoing board, I am satisfied we are leaving the Company in a strong position to continue under the direction of the new board: (1) the Company has the financial resources to pursue an appropriate path forward in a timely manner and meet current obligations and entitlements; (2) all information and resources needed by the incoming board are intact and available; (3) the ongoing commitment of the current management team has been secured; and (4) the outgoing leadership are available to assist the incoming board to effect a smooth transition." 

QRxPharma will proceed with the GM today at the offices of DibbsBarker, Lawyers, of Level 8, 123 Pitt Street, Sydney at 10:00am (AEST).  Attached is the address to be delivered by Peter Campbell (Director and Chairman of the meeting).

About QRxPharma
QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new pain management and abuse prevention products. The Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risks and improved patient outcomes. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc., Aspen Group and Teva Pharmaceuticals for the commercialisation of immediate release Moxduo in the US, Canada , Australia (including New Zealand and Oceania), South Africa and Israel . The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of Moxduo. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit www.qrxpharma.com .

Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

General Meeting Chairman's Address – Peter Campbell

9 July 2014

Thank you for your attendance at today's meeting. As you are aware, the Board called this general meeting of shareholders following receipt of a notice issued under section 249D of the Corporations Act 2001, from Walker Group. 

Proxies lodged by larger shareholders have made it clear they want change to the current Board of Directors. As a consequence Dr. Peter Farrell , Chairman of the Board of QRxPharma, and Dr. Gary Pace , founder, have resigned effective from immediately before the start of this meeting. With these resignations, Resolutions 1 and 2 listed in the Notice of General Meeting are redundant and will not be considered at the meeting.

I, ( Peter Campbell ) and Michael Quinn have also tendered our resignations from the Board of QRxPharma. These resignations will take effect from 5.00 pm 11 July, 2014 - this Friday, so as to give the new directors time to appoint one or more replacements and facilitate an orderly transition.

Although he has resigned as a director, Dr Gary Pace has agreed to continue as a consultant in support of intellectual property issues and regulatory interactions for QRxPharma. The Board thanks Dr Pace for his commitment to effect a smooth transition and transfer of information to the incoming Board of Directors of QRxPharma.

The requisition has been unsettling for management and staff so in the interest of shareholders the Board has taken steps to retain them and their expertise pending the decisions of the new board.  We are very appreciative of our employees' and consultants' goodwill under the circumstances.

Like all shareholders, your directors have been devastated by the recent turn of events. Throughout the clinical trials for Moxduo, the Company followed FDA guidance to meet the Combination Rule. The Company was encouraged by its interactions with the FDA leading up to June 2012 and was very disappointed at not receiving approval as a consequence of the revised interpretation in June 2012 by the FDA of the Combination Rule and its applicability to Moxduo. Despite the existing regulation that equivalence in efficacy and safety was required for approval, the FDA elected to ask for a clinical benefit for some particular patient population.

They then agreed that Study 022 and post hoc analyses could satisfy their requirements. That review took over 12 months during which time the FDA was under intense and controversial political pressure regarding opioid approvals. Unfortunately, at the April 2014 Advisory Committee meeting, the committee rejected Study 022's post hoc analyses, and preferred pre-specified outcomes and statistical metrics instead. Following this feedback, the FDA declined to approve Moxduo.  Given this history, the focus now turns to feedback from the FDA in the meeting later tonight, and what that means for the future of Moxduo and QRxPharma.

I would like to take this opportunity to thank my fellow Board members, senior management and the entire QRxPharma staff and consultants in both Australia and the US for their commitment and efforts over the past seven years.  The departing Board members wish the incoming Board and shareholders of QRxPharma every success.

SOURCE QRxPharma Limited

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 154

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 67

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 158

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 337

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Impact of Proposed Tariffs on Europe's Automotive Sector

Updated Category News Views 226

Understanding the Impact of Proposed Tariffs on the Auto Industry The recent political climate and proposed tariffs from former U.S. President Donald Trump signal significant changes ahead for global automakers. European car manufacturers, including giants like Volkswagen and Stellantis, may feel the ripple effects more acutely than expected. This article explores how...

Continue Reading
Corning Incorporated Reports Impressive Year-End Results

Updated Category News Views 431

Corning Incorporated's Remarkable Financial Performance Corning Incorporated (NYSE: GLW) has announced impressive financial outcomes for the fourth quarter and full year 2024. The results reflect the company's successful implementation of its 'Springboard' plan and position Corning for continuous growth as it enters 2025. Outstanding Fourth-Quarter Growth In the fourth...

Continue Reading
AAV Gene Therapy Landscape: Transforming Retinal Disease Treatments

Updated Category News Views 199

Introducing the AAV Gene Therapy for Retinal Diseases Adeno-associated virus (AAV) has emerged as an essential tool in the realm of gene therapy, particularly for treating hereditary retinal diseases caused by mutations in critical genes such as RPE65, CEP290, and CHM. This gene therapy approach is designed to address unmet medical needs, offering hope for long-term or...

Continue Reading
Rayonier Declares 4th Quarter Dividend and Company Outlook

Updated Category News Views 76

Rayonier Announces Fourth-Quarter Dividend Rayonier Inc. (NYSE: RYN), a prominent timberland real estate investment trust (REIT), has declared an impressive quarterly cash dividend of $0.285 per common share. Shareholders can expect this dividend to be paid on December 31, 2024, to those recorded by December 17, 2024. This announcement reflects Rayonier's dedication to...

Continue Reading
Cango Inc. Reports Record Financial Growth and Future Plans

Updated Category News Views 177

Cango Inc. Financial Highlights Cango Inc. (NYSE: CANG) a prominent name in Bitcoin mining and automotive transaction services, has released its unaudited financial results demonstrating significant achievements in the financial year. Robust Fourth Quarter Performance The fourth quarter of 2024 was particularly fruitful for Cango, showcasing total revenues of RMB668...

Continue Reading